Our Pricing

Understanding and Managing Wegovy Diarrhoea: Clinical Guidance from UK Pharmacists

Published on: June 03, 2026

Experiencing wegovy diarrhea side effects UK patients commonly report is a recognised gastrointestinal response to semaglutide treatment. At Cured Pharmacy, our UK-registered clinical team has supported thousands of patients through their weight loss journey, and we understand that managing side effects is crucial to treatment success. Diarrhoea typically occurs as your body adjusts to Wegovy, and with proper clinical guidance, most patients continue treatment successfully.

Why Wegovy Causes Diarrhoea: The Clinical Mechanism

Wegovy contains semaglutide, a GLP-1 receptor agonist that slows gastric emptying and modulates gut motility as part of its therapeutic action [1]. This alteration in digestive transit time can trigger diarrhoea, particularly during the initial dose-escalation phase when your gastrointestinal system is adapting to the medication.

In the STEP clinical trial programme, gastrointestinal side effects including diarrhoea were reported by approximately 30% of participants, with most cases classified as mild to moderate in severity [1]. The incidence was highest during the first 8-12 weeks of treatment, corresponding to the dose titration period from 0.25mg to the maintenance dose.

Superintendent pharmacist Tarun Kumar (GPhC 2233073) explains that semaglutide's effect on the gut-brain axis is central to its weight loss mechanism, but this same pathway can temporarily disrupt normal bowel patterns until physiological adaptation occurs [2].

How Long Does Wegovy Diarrhoea Last?

For most patients, diarrhoea associated with Wegovy improves significantly within 4-8 weeks as the body adapts to each new dose level [1]. The symptom typically peaks 2-3 days after dose escalation and gradually subsides over the following fortnight.

Clinical data from the STEP trials showed that while 30% of participants experienced diarrhoea at some point during treatment, fewer than 5% discontinued Wegovy specifically due to gastrointestinal side effects [1]. This suggests that with appropriate management strategies, the vast majority of patients can continue treatment successfully.

If diarrhoea persists beyond 2 weeks at a stable dose, or if you experience severe symptoms with dehydration, contact your prescriber immediately. Your UK clinician may recommend maintaining your current dose for an additional month before escalating, or adjusting your treatment plan to optimise tolerability.

Timeline of Gastrointestinal Adaptation

Week 1-4 (0.25mg): Mild gastrointestinal symptoms common as treatment initiates. Week 5-8 (0.5mg): Possible recurrence of diarrhoea with first dose increase, typically resolving within 10-14 days. Week 9-16 (1.0mg-1.7mg): Gradual improvement in tolerance as physiological adaptation progresses. Week 17+ (2.4mg maintenance): Most patients report minimal ongoing gastrointestinal symptoms at maintenance dose [2].

Evidence-Based Strategies to Manage Wegovy Diarrhoea

Dietary modification is the first-line approach our UK prescribers recommend. Reducing dietary fat intake to below 30% of total calories can significantly decrease gastrointestinal side effects, as high-fat meals exacerbate the delayed gastric emptying caused by semaglutide [3]. Focus on lean proteins, complex carbohydrates, and soluble fibre sources like oats and bananas.

Hydration management is critical. Aim for at least 2-2.5 litres of water daily, and consider oral rehydration solutions if diarrhoea is frequent. Avoid caffeine and alcohol, which can worsen dehydration and stimulate bowel motility further.

Timing your Wegovy injection consistently on the same day each week, preferably in the evening after your last meal, may help minimise daytime gastrointestinal disruption. Some patients find that injecting before a rest day allows them to manage symptoms more comfortably.

When to Contact Your Prescriber

Seek immediate clinical advice if you experience severe diarrhoea with more than 6 loose stools daily, signs of dehydration (dark urine, dizziness, reduced urination), blood in stools, or severe abdominal pain. These symptoms require urgent medical assessment to rule out complications and may necessitate temporary treatment interruption [2].

Wegovy Diarrhea Side Effects UK: What the Clinical Data Shows

The STEP 1 trial, which enrolled 1,961 adults with obesity, documented gastrointestinal adverse events as the most common side effect category [1]. Diarrhoea occurred in 29.7% of participants receiving semaglutide 2.4mg versus 15.8% in the placebo group, confirming a clear treatment-related effect.

Importantly, the trial data showed that gastrointestinal side effects rarely led to treatment discontinuation when appropriate clinical support was provided. Only 4.5% of participants discontinued due to gastrointestinal events, and most of these occurred during the initial 20 weeks of dose escalation [1].

Post-marketing surveillance data from the MHRA confirms that the UK safety profile of Wegovy aligns with clinical trial findings. Gastrointestinal side effects remain the most frequently reported, but serious complications are rare when treatment is properly supervised by UK-registered prescribers [4].

Comparing Gastrointestinal Tolerability Across Weight Loss Treatments

While all GLP-1 receptor agonists can cause gastrointestinal side effects, tolerability profiles differ slightly. Wegovy's once-weekly dosing may offer better overall tolerability compared to daily injections, as the extended pharmacokinetic profile allows for more gradual physiological adaptation [3]. Your UK prescriber will consider your individual tolerance and medical history when recommending the most appropriate treatment.

Genuine Wegovy Supply: Why Authenticity Matters for Safety

With ongoing supply challenges affecting weight loss medications across the UK, counterfeit and diverted products have entered the market. At Cured Pharmacy, every Wegovy pen is sourced directly from UK-licensed wholesalers and manufactured by Novo Nordisk to MHRA-approved specifications.

Counterfeit semaglutide products may contain incorrect doses, contaminants, or no active ingredient at all, creating serious safety risks and unpredictable side effects [4]. Our superintendent pharmacist Tarun Kumar personally oversees procurement to guarantee that every patient receives genuine, UK-licensed medication with full traceability.

All Wegovy prescriptions at Cured Pharmacy require completion of a clinical assessment by a UK-registered prescriber, ensuring appropriate patient selection and ongoing monitoring. This is a legal requirement for prescription-only medicines and a critical safety measure that illegitimate suppliers often bypass.

Starting Wegovy at Cured Pharmacy: Your Clinical Journey

Your Wegovy treatment begins with a comprehensive online consultation that takes under 3 minutes to complete. Our UK-registered prescribers review your medical history, current medications, weight loss goals, and suitability for semaglutide therapy, with particular attention to contraindications and risk factors.

If Wegovy is clinically appropriate, your prescription is issued and dispensed from our GPhC-registered pharmacy (9012511). Wegovy is available from £79.00, with transparent pricing shown before consultation. Your medication arrives in 100% discreet packaging with full patient information leaflets and clinical guidance on managing potential side effects.

Ongoing clinical support is included throughout your treatment. If you experience persistent diarrhoea or other side effects, our pharmacy team is available on (+44) 116 4646009 during business hours, and your prescriber can adjust your treatment plan as needed to optimise both efficacy and tolerability.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Semaglutide (Wegovy): reminder of the importance of proper patient monitoring and supply chain integrity. Drug Safety Update, 16(8). https://www.gov.uk/drug-safety-update [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and should only be used under proper medical supervision.